Table 2.
Circulating microRNA-126 according to pato-anatomical characteristics
| Characteristics | Baseline | P | before operation | P | Follow-up | P | |||
|---|---|---|---|---|---|---|---|---|---|
| N | Median (95% CI) | value | N | Median (95% CI) | value | N | Median (95% CI) | value | |
| Perforation | |||||||||
| Yes | 6 | 0.77 (0.33-6.96) | 0.459 | 8 | 1.08 (0.29-2.42) | 0.389 | 5 | 1.33 | 0.553 |
| No | 51 | 1.06 (0.83-1.29) | 49 | 0.83 (0.75-0.96) | 48 | 1.00 (0.81-1.21) | |||
| Fixation | |||||||||
| Yes | 17 | 1.06 (0.88-1.94) | 0.246 | 15 | 1.50 (0.81-2.14) | 0.002 | 12 | 1.43 (0.99-2.95) | 0.080 |
| No | 40 | 1.02 (0.72-1.27) | 42 | 0.78 (0.65-0.87) | 41 | 0.98 (0.77-1.15) | |||
| Histology | |||||||||
| Adenocarcinoma | 43 | 1.41 (0.80-1.35) | 0.369 | 46 | 0.82 (0.73-0.94) | 0.429 | 41 | 1.09 (0.90-1.33) | 0.216 |
| Mucinous | 10 | 0.83 (0.49-2.07) | 8 | 0.91 (0.53-2.03) | 9 | 0.81 (0.45-1.77) | |||
| Othera | 4 | 1.02 | 3 | 1.09 | 3 | 0.73 | |||
| Malignancy grade | |||||||||
| 1+2 | 31 | 0.88 (0.70-1.32) | 0.080 | 36 | 0.79 (0.59-0.94) | 0.085 | 31 | 1.01 (0.79-1.35) | 0.448 |
| 3 | 18 | 1.28 (0.98-1.77) | 11 | 1.09 (0.67-1.32) | 12 | 0.93 (0.47-1.35) | |||
| Not evaluable | 8 | 0.64 (0.41-2.07) | 10 | 0.87 (0.65-2.03) | 10 | 1.03 (0.81-1.82) | |||
| Perineural invasion | |||||||||
| Yes | 8 | 0.93 (0.33-1.32) | 0.275 | 7 | 0.64 (0.29-0.94) | 0.021 | 4 | 1.47 | 0.449 |
| No | 49 | 1.06 (0.83-1.31) | 50 | 0.87 (0.78-1.08) | 49 | 1.00 (0.85-1.22) | |||
| Tumor budding | |||||||||
| Yes | 8 | 1.16 (0.33-1.43) | 0.971 | 8 | 0.83 (0.29-1.62) | 0.858 | 5 | 1.09 | 0.950 |
| No | 47 | 0.98 (0.80-1.29) | 47 | 0.83 (0.75-0.99) | 47 | 1.01 (0.85-1.31) | |||
| Not evaluable | 2 | 2.79 | 2 | 1.76 | 1 | 0.99 | |||
| MSI status | |||||||||
| MSI | 16 | 1.11 (0.86-1.43) | 0.495 | 13 | 1.31 (0.82-1.50) | 0.044 | 12 | 0.87 (0.53-2.51) | 0.733 |
| MSS | 38 | 1.03 (0.66-1.32) | 42 | 0.78 (0.67-0.87) | 38 | 1.08 (0.79-1.35) | |||
| Not evaluable | 3 | 0.83 | 2 | 0.91 | 3 | 1.01 | |||
| pT categoryb | |||||||||
| pT0 | 1 | 1.06 | 2 | 0.72 | 2 | 2.09 | |||
| pT1 | 0 | 0 | 0 | ||||||
| pT2 | 7 | 0.83 (0.50-2.98) | 10 | 0.79 (0.54-1.08) | 9 | 0.90 (0.73-1.35) | |||
| pT3 | 42 | 1.08 (0.80-1.32) | 0.458 | 37 | 0.94 (0.82-1.32) | 0.042 | 37 | 1.09 (0.89-1.35) | 0.018 |
| pT4 | 7 | 0.95 (0.33-2.07) | 8 | 0.66 (0.29-0.81) | 5 | 0.44 | |||
| pN categoryc | |||||||||
| pN0 | 38 | 1.15 (0.95-1.35) | 37 | 0.84 (0.67-0.99) | 36 | 1.00 (0.85-1.16) | |||
| pN1 | 11 | 0.70 (0.41-2.07) | 0.036 | 14 | 0.83 (0.64-1.55) | 0.587 | 11 | 1.35 (0.42-1.77) | 0.924 |
| pN2 | 8 | 0.64 (0.49-0.93) | 6 | 0.86 (0.31-2.03) | 6 | 1.09 (0.39-3.86) | |||
| Converted | |||||||||
| Yes | 27 | 1.15 (0.83-1.48) | 0.103 | 27 | 0.82 (0.65-0.99) | 0.955 | 27 | 0.99 (0.85-1.16) | 0.852 |
| No | 30 | 0.89 (0.62-1.27) | 30 | 0.84 (0.76-1.09) | 26 | 1.22 (0.48-1.77) | |||
CI: confidence interval; MSI: microsatellite instability; MSS: microsatellite stable; N: number.
Confidence intervals are not calculated for cases with less than six individuals N differs according to availability of blood samples [Supplementary Figure 1] (377KB, pdf) . aOther includes three low differentiated adenocarcinomas and one small cell/neuroendocrine carcinoma bP-value refer to the comparison pT4 vs. pT0-3 cP-value refer to the comparison pN0 vs. pN1-2